Navigation Links
John Theurer Cancer Center brings leading experts for its Ninth Annual Neuro-Oncology Symposium
Date:5/9/2013

Hackensack NJ (May 9, 2013) - John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will host its Ninth Annual Neuro-Oncology Symposium on Friday, May 17th from 8:00am-1:00pm. Experts from MD Anderson, Memorial Sloan Kettering Cancer Center, Penn State Milton S. Hershey Medical Center, and the Cleveland Clinic will present advances in multidisciplinary care for cancers of the central nervous system.

"Our guest speakers are among the nation's leaders in neuro-oncology," said Samuel Goldlust, M.D., Co-Chief of the Brain and Spine Institute at John Theurer Cancer Center. "They will present their perspectives on the latest neurosurgical and medical treatment options and those on the horizon."

This program is intended for all healthcare providers who care for patients with central nervous system (CNS) cancers. At the conclusion of the program participants will be able to identify current standards of care, describe benchmark data that led to current treatment paradigms, and review recent advances in multidisciplinary care and the potential impact on survival and quality of life.

"This is an opportunity for healthcare professionals in the tristate area involved in the treatment of CNS cancers to learn about advances in research that shape the way we care for patients. " said George Kaptain, M.D., Co-Chief of the Brain and Spine Institute.

Featured speakers and their presentations include:

  • John DeGroot, M.D., Associate Professor, Department of Neuro-Oncology, University of Texas, M.D. Anderson Cancer Center: Anti-Angiogenic Therapy: Efficacy and Mechanisms of Resistance
  • Michael J. Glantz, M.D., Professor Neurosurgery, Medicine and Neurology, Penn State Milton S. Hershey Medical Center: Neoplastic Meningitis: How Can We Stop Snatching Defeat From The Jaws of Victory?
  • Jason T. Huse, M.D., Ph.D., Assistant Attending, Department of Pathology, Memorial Sloan-Kettering Cancer Center: The Emerging Molecular Foundations of Diffuse Gliomas
  • Michael Vogelbaum, M.D., Ph.D., Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation: Surgery for Gliomas: How Far Should We Go?

"It's an exciting time for neuro-oncology at our Brain and Spine Institute," said Chief Emeritus Mark S. Pascal, M.D. "Recently we have seen tremendous programmatic growth, including in our Gamma Knife radiosurgery center, robust clinical trial program, and dedicated support services for neuro-oncology patients."

The conference will be held at John Theurer Cancer Center, 92 Second Street, Hackensack, NJ 07601. HackensackUMC designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s), physicians should only claim credits commensurate with the extent of their participation in the activity. This conference is complimentary but advanced registration is required. To register or for more information, please contact Maryann V. Lederhilger at 551-996-1162 or mlederhilger@HackensackUMC.org.

"Oncology is moving at an accelerated pace," said Andre Goy, M.D., M.S., Chairman and Director, Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates. "We believe it is more important than ever to help physicians and healthcare professional stay up to date with the latest research and treatment best practices."

"John Theurer Cancer Center is committed to helping healthcare professionals gain access to, and knowledge of, the latest advancements in cancer care, and we are proud to offer continuing education programs like the neuro-oncology symposium to help fulfill this goal," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer Care Associates.


'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
646-476-3845
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. John Theurer Cancer Center hosts first Womens Oncology Conference
2. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
3. John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
4. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
5. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
6. Research finds identifies social needs of young people with cancer
7. Popular diabetes drug does not improve survival rates after cancer: Study
8. Your immune system: On surveillance in the war against cancer
9. Fun and friends help ease the pain of breast cancer
10. Missouri Man Alleges Five Years of Actos Use Caused his Bladder Cancer; Parker Waichman LLP Files Lawsuit on Victim’s Behalf
11. Just How Might Exercise Lower Breast Cancer Risk?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: